Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-4

Eli Lilly · Phase 3 · Completed · Enrollment 783

NCT04660643

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

98.4969
≥5%
≥10%
≥15%
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
Tirzepatide (lead-in)n/rn/rn/rn/r
Tirzepatide MTD98.49%n/rn/rn/r
Placebo69%n/rn/rn/r

Not shown

  • Tirzepatide (lead-in): endpoint not reported